Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC). One strategy to improve HCC therapy is to combine agents that target key signaling pathways. Aberrant mesenchymal-epithelial transition factor (c-Met) activation is associated with a variety of human malignancies and therefore represents a target for therapy...

Background: Programmed death protein-1 (PD-1) inhibitors and liver transplantation (LT) are alternative treatments for hepatocellular carcinoma (HCC) patients. The application of PD-1 HCC therapy increases T cell immune activity, while immunosuppression is required patients receiving transplantation. More clinical investigation to determine methods balance these treatment effects. In this artic...

patients and methods this was a retrospective study including 207 consecutive patients who were enrolled using computerized hepatocellular carcinoma database consisting of 105 patients who underwent combined tace with rfa, and 102 patients who underwent tace alone with long-term follow-up. results the complete remission rate was meaningfully higher in the combination group (97.1%, 102/105) than...

The proliferation of hepatocellular carcinoma (HCC) cells is one of the leading causes of liver cancer mortality in humans. The inhibiting effects of matrine on HCC cell proliferation have been studied, but the mechanism of that inhibition has not been fully elucidated. Since, apoptosis plays an important role in HCC cell proliferation. We examined the apoptosis-inducing effect of matrine on tu...

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related death worldwide. Despite advances in prevention techniques, screening, new technologies both diagnosis treatment, incidence mortality continue to rise. Cirrhosis remains important risk factor for development HCC regardless etiology. Chronic medical conditions such as diabetes mellitu...

Hepatocellular carcinoma (HCC) has an increasing incidence worldwide, and it is the leading cause of death in patients with cirrhosis. The criteria for the diagnosis of Hepatocellular carcinoma (HCC) have been defined at the Barcelona2000 EASL (European Association fof the Study of the Liver) conference1. Not so defined were the staging criteria, a useful tool to the physician to choose the mos...

Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Hepatitis B virus infection is one of the most important etilogical factors of HCC. In this case report, a patient with HCC previously infected and having ongoing immunity against hepatitis B virus will be discussed. How to cite this article Ates I, Kaplan M, Demirci S, Altiparmak E. A Hepatocellular Carcinoma Cas...

[Original]Hepatocellular carcinoma (HCC) is the most common primary neoplasm of liver, which arises from parenchymal cells liver.1 Hepatocellular usually develops in setting chronic background liver disease, such as cirrhosis or hepatitis B C infection. The diagnosis HCC relies heavily on diagnostic imaging, and high sensitivity specificity Liver Imaging Reporting Data System (LI-RADS) classifi...

Hepatocellular carcinoma (HCC) is a primary tumor of the liver that develops in setting chronic disease. HCC difficult to diagnosis due it requiring use multiple imaging modalities with goal detect tumors when they are less than or equal 2 cm size allow all possible treatment options be used. Herein, we discuss 69-year-old male stage IV cancer residing hospice presenting left middle finger oste...

Background and AimsStress granules (SGs) as membrane-less cytoplasmic foci formed in response to unfavorable external stimuli could promote cancer cells adapt hostile environments. Hepatocellular carcinoma (HCC) is prone be highly aggressive once diagnosed, which markedly reduces patient survival time. Therefore, it crucial develop valid diagnostic markers prognosticate HCC prognosis, promotes ...